Quarterly report · Q3
2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.18T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.05T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥29.9bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥20.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥31.2bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥30.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥14.9bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.50T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.44T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.04T | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥464.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥200.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥107.92 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.22 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.24 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥290m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.94T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.92T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥14.0bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥25.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥40.0bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥28.2bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥11.7bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥484m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥200.4bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥200.0bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥395m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥2.18T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥372m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.82T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.81T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥16.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥25.8bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥992m |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥186.8bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥186.3bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥429m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥2.07T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥2.05T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥24.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥19.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 381
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)細 矢 聡 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)高 野 浩一郎 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)斉 藤 直 樹 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 2047935000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 2179803000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 2696069000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 21992000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 31215000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 32831000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 14822000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 20871000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 25786000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 21186000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 23461000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 27641000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 481880000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 464343000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 488335000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 1438692000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 1500114000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 1339852000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 73.24 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 107.92 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 127.42 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.335 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.309 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.364 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 38.64 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 48.22 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 202840000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 202840000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 202840000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 202840000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 15420700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 187193200 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1871932 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 226100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 202840000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 1871932 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 15420700 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |